Oncoloxía
Hospital Miguel Servet
Zaragoza, EspañaPublicacións en colaboración con investigadores/as de Hospital Miguel Servet (64)
2024
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583
-
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis
Clinical and Translational Oncology
-
Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study
Journal of Nutrition, Health and Aging, Vol. 28, Núm. 8
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Breast Cancer Research and Treatment, Vol. 206, Núm. 2, pp. 317-328
-
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study
Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 1896-1907
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
2023
2022
-
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program
Oncotarget, Vol. 13, Núm. 1, pp. 812-827
-
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study
Cancers, Vol. 14, Núm. 19
-
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer, Vol. 168, pp. 12-24
-
Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study
European Journal of Clinical Nutrition, Vol. 76, Núm. 9, pp. 1343-1346
2021
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
European Journal of Cancer, Vol. 156, pp. 70-82
-
Trajectories of alcohol consumption during life and the risk of developing breast cancer
British Journal of Cancer, Vol. 125, Núm. 8, pp. 1168-1176
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148
-
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Lung Cancer, Vol. 150, pp. 90-96
-
Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study
BMC Psychology, Vol. 8, Núm. 1
-
Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2020), 22, 6, (823-834), 10.1007/s12094-019-02211-x)
Clinical and Translational Oncology
-
Liquid biopsy in oncology: A consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia, Vol. 53, Núm. 4, pp. 234-245
-
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 22, Núm. 6, pp. 823-834